AKT1 and Hyperglycemia: However, in IPATunity130 Cohort B, the proportion of patients experiencing hyperglycemia was lower than in trials of other PI3K/AKT inhibitors [20, 23–25] and similar in the two treatment arms (14% with ipatasertib plus paclitaxel vs 12% with placebo plus paclitaxel).